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Abstract 
This paper brings attention to a case report of osteoporosis diagnosed in a 67-year-old female 
due to a low trauma fracture.  The individual was deemed high fracture risk, and unestablished in 
primary care. The drug class of Selective Serotonin Reuptake Inhibitors (SSRIs) and their 
recently identified risk of decreasing bone mass density, increasing osteoporosis, and ultimately 
doubling fracture incidence will be explored.  Current osteoporosis screening guidelines are 
examined and criticized in relation to the presented evidence.  Evidence based articles and up to 
date practice recommendations were reviewed.  The results of multiple meta-analyses concluded 
that SSRIs have a significant negative impact on bone metabolism, increasing fracture risk.  The 
high rates of unscreened osteoporosis, the current prevalence of the disease, and the lack of 
inclusion of SSRI use in the current fracture risk assessment prove significant clinical relevance 
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The Increased Risk of Osteoporosis with Selective Serotonin Reuptake Inhibitor Use and 
The Need for Adjusted Screening Methods 
 Osteoporosis is defined as a “chronic skeletal disease marked by microarchitectural 
deterioration of the bone matrix and depletion of bone mineral density (BMD), with a 
consequent increased risk for fragility fracture” (Fernandes, Hodge, Pasco, Berk & Williams, 
2016).  An article by Gillespie and Morin (2017) discusses the current disparities in osteoporosis 
screening for women.  A retrospective six-year study of over 1.6 million women over the age of 
50 revealed that osteoporosis screening was low overall.  Only 21.2% of women ages 50-64, 
26.5% ages 65-79, and 12.8% ages 80 and above were appropriately screened (Gillespie & 
Morin, 2017).  This represents a clear discrepancy in osteoporosis screening. 
 Osteoporotic fractures in post-menopausal women currently have a higher incidence rate 
than stroke, myocardial infarction, and breast cancer combined.  Fractures occurring in the 
osteoporotic population represent a financial public health issue as they increase disability and 
mortality risk (Watts & Manson, 2017).  The commonality of osteoporosis along with the current 
disparities in screening creates an outrageous health care concern. 
Current osteoporosis screening guidelines from the United States Preventative Services 
Task Force (USPSTF) recommend screening women aged 65 years and older or in younger 
women with an equivalent fracture risk.  Up to Date (2017) advises to perform a fracture risk 
assessment in all adults, post-menopausal women, men over 60, or any patient with a history of a 
low trauma fracture.  The fracture risk assessment was introduced in 2008 by the World Health 
Organization (WHO), termed as the Fracture Risk Assessment Tool (FRAX).  The FRAX 
estimates the 10-year risk of a major osteoporotic fracture for an untreated patient using the sum 
of clinical risk factors.   
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Over the past two years, meta-analysis reviews have revealed that the use of SSRIs at 
therapeutic levels for depression and anxiety have a negative effect on bone structure, decreasing 
bone mineral density and increasing fracture risk (Bruyere & Reginster, 2015) (Fernandes, 
Hodge, Pasco, Berk & Williams, 2016).  Currently, the FRAX does not consider SSRI use in 
calculating one’s fracture risk.  This paper gives its readers the evidence to include SSRI use into 
the fracture risk assessment, along with the importance of adjusted screening methods for the 
SSRI population. 
Background 
 A 67-year-old female presents for an 8-week post-operative follow up appointment for a 
right hip replacement due to a total right hip fracture.  She has little primary care history.  She 
displays high fracture risk qualities of post-menopausal age, current 1.5 ppd smoker with a 75-
pack year history, low body weight, and does not participate in weight bearing exercise.  Per 
patient report of the low trauma injury causing her fracture and additive risk factors, a dual-
energy x-ray absorptiometry (DXA) scan was ordered, and revealed the diagnosis of 
osteoporosis.  The current screening guidelines previously stated by the USPSTF are in place 
with a rationale that half of all post-menopausal women will experience an osteoporotic-related 
fracture in their life (Gillespie & Morin, 2017). The previously stated screening disparities may 
rise from the ill-defined wording and ambiguity of the current guidelines. 
As formerly discussed, to calculate fracture risk, current practice guidelines listed in Up 
To Date (2017) recommend using the FRAX assessment tool.  The FRAX tool is meant to allow 
providers the ability to assess fracture risk with or without bone mineral density information.  
Clinical information used to assess risk include; age, gender, weight, height, previous fracture, 
parent fractured hip, current smoking status, current glucocorticoid use or a history of more than 
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a 3-month dose of prednisone 5mg/day, rheumatoid arthritis, secondary osteoporosis, alcohol use 
of 3 or more units/day, and can consider femoral neck BMD.  Secondary osteoporosis is present 
when a patient has a disease strongly associated with osteoporosis.  Stated on the FRAX 
calculator, this includes “type I diabetes, osteogenesis imperfecta in adults, untreated long 
standing hyperthyroidism, hypogonadism or premature menopause (<45 years of age), chronic 
malnutrition, or malabsorption and chronic liver disease.” (Fracture Risk Assessment Tool, 
http://www.shef.ac.uk/FRAX/index.aspx).  SSRI use is not taken into account in any area of the 
FRAX screening tool. 
Recent reviews have looked at longitudinal, cross-sectional, prospective cohort, and 
randomized controlled trials and have unanimously stated that SSRI use independently decreases 
bone health, leading to increased developments of osteoporosis.  Additionally, SSRIs 
independently doubled the occurrence of fragility fractures associated with osteoporosis 
(Fernandes et al, 2016).  SSRIs are the first line therapy worldwide for treatment of depression, 
mood, and anxiety disorders, especially in the older adult population due to the favorable adverse 
effect profile (Bruyere & Reginster, 2015).  With the evidence presented here and the high 
prevalence of SSRI use, the absence of its inclusion in the Fracture Risk Assessment Tool 
(FRAX) needs to be addressed. 
The purpose of this report is to relate the defined terms and guidelines of osteoporosis to 
recently studied SSRI effects on bone mass, and further, to identify current disparities in fracture 
risk assessments and improve screening efforts related to osteoporosis.   
Case Report 
 A 67-year-old female presents for an 8-week post-operative appointment for a right hip 
replacement due to a total right hip fracture.  The total right hip fracture occurred from a fall in 
INCREASED OSTEOPOROSIS RISK WITH SSRI USE 7 
 
the bath tub.  The patient states she is feeling O.K. today, and denies any concerns or complaints. 
She has little primary care history, and inconsistent health care visits.  She would like to discuss 
establishing care at this clinic.  Patient is Caucasian. Past medical history of hypertension, 
depression, and breast cancer of the right breast. Denies any history of fractures. Denies any drug 
allergies.  She is widowed with three grown children.  Currently smoking 1.5 ppd for 50 years 
(75 pack years).  Rarely uses alcohol and does not exercise.  She is retired, and states she is 
relatively inactive.  She denies being up to date on any of her screenings besides a mammogram 
in 2016 that was unremarkable.  Current medications are Lisinopril 10mg po daily and arimidex 
1mg po daily.  Today’s vital signs are: BP: 132/70, HR: 78, RR:16, O2: 96%, Weight: 121lbs. 
 She denies any pain today.  She does occasionally experience mild pain at home, mostly 
in the mornings, and takes 650mg of Tylenol every 6 hours as needed.  She states she graduated 
from her assigned physical therapy post-surgery.  She denies any fevers, chills, redness, 
drainage, or swelling at the surgical site. 
 In an in-depth review of systems, she further denies headache, changes in vision, recent 
illness, shortness of breath, chest pain, heart palpitations, muscle weakness, numbness or 
tingling, nausea, vomiting, diarrhea, dysuria, polyuria, or any other pain unrelated to her hip.  
She denied any issues with her mood now, but does have a history of taking sertraline (Zoloft) 
for depression symptoms in the past.  
 Physical exam is unremarkable. Patient is good spirits, and happy with the results of her 
recovery. She is moving all extremities equally, and transferring well onto exam table.  No 
grimacing or guarding noted. Surgical site is well approximated, and healing appropriately.  No 
redness, drainage, bruising or swelling noted to surgical site.  She is alert and cooperative 
throughout exam.  No signs of distress.  Non-diaphoretic.  Head is normocephalic and 
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atraumatic. No adenopathy. Normal S1, S2 heart sounds with regular rate and rhythm. Radial and 
distal pulses +2.  Capillary refill less than 3 seconds. No peripheral edema or swelling noted.  
Breath sounds auscultated are clear and equal throughout all lung fields.  Good air exchange 
noted throughout.   
 Following the physical exam, we discussed future screenings and interventions that she 
should have at a follow up appointment to establish primary care.  These included a 
colonoscopy, follow up mammogram, a low dose CT scan given her smoking history, up to date 
immunizations, a complete metabolic panel, CBC, lipid profile, and TSH.  It was explained to 
the patient that a dual energy x-ray absorptiometry (DEXA scan) should be complete today.  This 
is needed imaging to evaluate her bone density.  Given the nature of her fracture, and 
osteoporosis risk factors, it is suspected that she has osteoporotic changes in her bones. 
 The DEXA scan resulted with a T score of -4.1 of the lumbar spine, and of -2.1 in the 
femoral neck.  These scores are significant, and the conclusion is a diagnosis of osteoporosis 
with a high fracture risk.  These results were reviewed with the patient.  We discussed associated 
risk factors of smoking, post-menopausal age, low body weight, taking an aromatase inhibitor, 
and her sedentary lifestyle.  A treatment plan was created with the patient and includes a 
smoking cessation plan, weight bearing exercises for 30 minutes 3 times a week, begin taking 
1000mg of a calcium supplement and 800 units of vitamin daily, and to take alendronate 
(Fosamax) 70mg PO once a week.  Education was provided on adverse drug reactions and the 
importance of taking Fosamax with a large glass of water, 30 minutes before the first meal or 
medication of the day.  Additionally, avoid laying down for 30 minutes after taking.  Instructed 
patient to follow up with dentist annually. The patient verbalized understanding, and agreed with 
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plan of care.  She denied any further questions or concerns. She will follow up in two weeks for 
an annual physical and to schedule additional primary care screenings. 
Literature Review 
 The above case report presents a high-risk osteoporosis patient.  Due to her lack of 
regular visits with a provider, she did not have the opportunity to be appropriately screened prior 
to fracture occurrence.  As previously stated, a 2017 study revealed that only 21.2% of women 
ages 50-64, 26.5% ages 65-79, and 12.8% ages 80 and above were appropriately screened for 
osteoporosis (Gillespie & Morin, 2017).  This data shows that even post-menopausal women 
visiting their provider regularly, are not being appropriately screened for osteoporosis. Had this 
patient been established in primary care, or had regular clinic visits, she may have had a “26.5%” 
chance of being appropriately screened.  Gillespie and Morin (2017) show a clear gap in 
preventative care related to osteoporosis.  Additionally, recent studies reveal a strong relationship 
between depression, SSRI use, decreased bone density, and increased fracture occurrence.  This 
additional information would put this patient in an even higher baseline risk category for 
osteoporosis.  A literature review was conducted on the current evidence available on 
osteoporosis screening, and the relationship between SSRIs and bone density.  By implementing 
appropriate and early screening methods, high risk osteoporosis patients have the opportunity for 
early interventions and lifestyle management.  Early interventions may decrease fracture 
occurrence, ultimately improving patient quality of life, and driving down health care costs.  
Current Screening and Management Recommendations 
Screening for osteoporosis is mildly unclear, and autonomy is given to the provider to 
assess risk factors on an individual basis.  This may account for the low screening numbers in 
postmenopausal women.  Kleerekoper (2015), writes for the Up To Date practice guidelines 
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stating, “Screening for osteoporosis involves fracture risk assessment and measurement of bone 
mineral density (BMD).  We recommend assessing risk factors for fracture in all adults, 
especially postmenopausal women, men over 60 years, and in any individual who experiences a 
fragility or low-trauma fracture.”  Here the author’s recommendations differ from the USPSTF 
recommendations for screenings for all adults versus adults over 65 years of age.  Risk factors 
are listed as: advanced age, previous fracture, long term use of glucocorticoid therapy, low body 
weight (less than 127lb), family history of hip fracture, cigarette smoking, and excess alcohol 
intake.  It is recommended to use clinical information to assess fracture risk using the FRAX tool 
previously discussed.  USPSTF recommends screening women aged 65 years and older or in 
younger women with an equivalent fracture risk.  As more findings arise showing adverse effects 
on bone health from a variety of risk factors, risk assessments should be completed in all adults. 
USPSTF and Up to Date (2015), suggest bone mineral density (BMD) testing using a 
DEXA scan in women 65 years of age and older, and in younger postmenopausal women with 
clinical risk factors for fracture.  BMD testing in men is only suggested if they present with 
clinical risk factors of low bone mass and fracture. 
Up to Date bases these recommendations off a well-designed randomized control trial 
that concluded that screening is directly related to a reduced fracture risk.  The published trial 
used 4800 postmenopausal women (45-54 years), and randomly placed them in either a BMD 
screening or no screening group.  After an average of nine years, 37-52% of screened women 
reported using hormone replacement therapy, or other osteoporosis medications compared to 22-
45% of unscreened women (Barr, Stewart, Togerson & Reid, 2010).  This study showed that 
screening for osteoporosis increases the percentage of women that initiated anti-osteoporotic 
medications as an early intervention. 
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The management guidelines discussed address the microarchitectural disruption that 
occurs in osteoporosis, as well as lifestyle regimens to prevent, or treat bone loss.  Intaking 
enough calcium and vitamin D daily prevents excessive bone resorption.  Supplementation 
guidelines are based off meta-analysis reports.  Combined intake amounts from diet and 
supplementation should total at 1200mg of calcium, and 800 international units of vitamin D 
daily.  Guidelines further recommend a total intake of 1000mg of calcium, and 600 international 
units of vitamin D for premenopausal women, or men with osteoporosis (Rosen, 2016, as 
presented in Up to Date).  The U.S. Food and Drug Administration (FDA) currently has four 
medications approved to improve bone strength.  Options include oral bisphosphonates weekly 
or monthly, or nonoral bisphosphonates administered biannually or annually.  Bisphosphonates, 
supplementation, and lifestyle management to reduce the risk of fracture is the first line 
treatment regimen for osteoporosis (Watts & Manson, 2017).  Early interventions of these 
management guidelines would benefit patients screened as high fracture risk. 
Pathophysiology of Bone Metabolism and the SSRI impact 
 Osteoblasts, osteoclasts, and osteocytes are the three major cells types that create the 
bone.  Continuous bone remodeling is done as osteoclasts perform bone resorption.  This is 
followed by bone generation of the osteoblasts, which create the osteocytes that interconnect and 
insert themselves into the bone matrix.  This process is how bone mass is preserved, and how it 
remodels in response to physical stressors (Fernandes et al., 2016).  Altering this bone 
remodeling process is how serotonin disrupts the bone matrix. 
 Serotonin is commonly known to be produced in the brain, having a centrally inhibitory 
effect on the sympathetic nervous system.  In the treatment of depression and anxiety, SSRIs 
increase the level of serotonin in the synapse for the post-synaptic cell to uptake.  This is done by 
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inhibiting the reuptake of serotonin of the pre-synaptic cell.  Unknown to common belief, 
serotonin is also produced peripherally.  Highest concentrations of peripherally produced 
serotonin are found in the gastrointestinal tract, but the osteoclasts in the bone microenvironment 
release peripheral serotonin as well.  This peripheral serotonin from osteoclasts has a direct 
effect on osteoblastic serotonin receptors, inhibiting bone remodeling.  In this manner, 
osteoclast-derived serotonin act as paracrine and autocrine to regulate the process of bone 
remodeling.  In the instance of SSRI use, elevated serotonin levels are induced both centrally and 
peripherally (Fernandes et al., 2016).   These peripheral elevated serotonin levels are increasing 
the signaling to the osteoblasts to inhibit bone formation, decreasing bone mass, and increasing 
the risk of osteoporosis and fracture. 
Depression and Osteoporosis. 
 Depression as a disease has been previously associated with bone deterioration, and 
increased fracture risk.  Like osteoporosis, depression is a highly prevalent disease that is 
lifelong and debilitating.  The associated lack of motivation, low energy, and impaired cognitive 
functioning all impact one’s quality of life.  Besides their association, the relationship between 
depression and osteoporosis remains unclear.  More recently, there has been strong evidence to 
support the hypothesis that the chemical imbalance of depression alters bone metabolism, 
increasingly when SSRI treatment is used.  In a review of current studies, even after known risk 
factors for osteoporosis were eliminated, clinical depression and depressive symptoms were 
shown to remain negatively associated with decreased bone mass.   The evidence supports that 
negative implications on bone mass occur at the onset of depressive symptoms, not just later in 
life (Fernandes et al., 2016).  A review revealed that people with depression versus without 
exhibited “lower bone mass at the spine, hip, forearm, with a stronger association observed for 
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pre-menopausal than for post-menopausal women” (Fernandes et al., 2016, p.23).  While 
studying SSRI use and it’s indication on bone health, it is imperative to address the independent 
association of depression and decreased bone health. 
 Furthermore, a study was completed to study the effects on anxiety disorders and bone 
health.  Anxiety and depression are now commonly thought to be on a continuum.  With 
depression associated with decreased bone health in the past, this study revealed anxiety 
disorders impact bone metabolism negatively as well.  High levels of stress seen in anxiety 
disorders decrease osteocalcin levels that are naturally increased during bone construction, which 
decreasing bone density.  While studying SSRI use to treat anxiety disorders, the authors 
concluded a significant negative relationship between duration of SSRI treatment and BMD 
values (Ak et al., 2015).  
Details of SSRI use. 
 Selective serotonin reuptake inhibitors are the most used antidepressants throughout the 
world.  They make up 60% of all antidepressants prescribed.  A Canadian cohort study over 5 
years studied 5000 adults over 50, and reveals that daily use of SSRIs doubled the risk of 
fragility fractures, even after confounding variables were adjusted.  Additionally, it found that 
the fracture risk was dose dependent, but that intermittent users risk was equal to daily users.  
Further supporting the results, another cohort study of over 7000 adults over age 55, revealed 
that current SSRI user’s risk of vertebral fractures was over double the risk of past SSRI users 
and tricyclic antidepressants users.  This study also clarified that SSRI use was an independent 
risk factors of depressive symptoms.  Additional meta-analysis only potentiates the argument 
that SSRI use has negative implications on bone metabolism, increasing risk of osteoporotic 
fractures (as stated in Fernandes et al., 2016).  
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 The peripheral serotonin receptors and transporters in bone cells are directly where 
changes in serotonin impact bone homeostasis.  In a trial on mice, by disrupting the serotonin 
transporter gene, or by inhibiting the serotonin transporter gene by pharmacologic use, as in 
SSRIs, resulted in low bone mass.  These results were similar in growing and adult mice 
(Fernandes et al., 2016). The data generated from multiple animal trials presents evidence that 
serotonin plays a direct role in bone homeostasis, and that the inhibition of the serotonin 
transporter through SSRI use has a direct anti-anabolic effect on bone metabolism (Fernandes et 
al., 2016).  These animal studies prove the relationship between SSRIs and bone health even in 
the absence of other human osteoporosis risk factors. 
 Bruyere and Reginster (2015) looked at fracture outcomes through a review of the 
literature that further backs the presented data, stating there is a direct relationship with SSRI use 
and decreased BMD.  Their analysis performed a quantitative assessment of the relationship 
between SSRIs and fracture risk.  Results were unanimous and showed that SSRI use was 
associated with an “increase in fractures of all types, non-vertebral, hip, and spine fractures”. 
(Bruyere & Reginster, 2015, p.66).  They discussed that the increased risk of fracture has been 
supported by “several distinct populations, using various study designs with bone density, bone 
loss, or fractures as outcomes…these results are consistent after adjustments for confounding 
variables such a age, body mass index, lifestyle factors, and history of fractures.” (p.66).  The 
results of this systematic review present substantial strength in the argument that SSRIs need to 
be more routinely included in fracture risk assessments.  
 Additionally, Bruyere and Reginster (2015) found that the strength of the association of 
SSRIs and decreased BMD differs based on SSRI dose, duration, time, age, or sex.   They go on 
to state a further meta-analysis has been done taking these factors into account and that the 
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“strength of the association decreased with a longer window of SSRI administration” (Bruyere & 
Reginster, 2015, p.67).  Additional cohort studies presented here support that the highest risk of 
fracture is found at SSRI initiation-8 months, remaining elevated until 18 months.  A 10-year 
Canadian cohort study revealed that higher doses of SSRIs at base line was associated with high 
fracture risk.  Of equal importance, a Dutch case control study showed a significant association 
between the discontinuation of SSRI use and the rapid decreased risk of fracture as well (Bruyere 
& Reginster, 2015).  More studies need to be performed to define the details of how SSRI use 
effect bone health, but there is sufficient evidence of their direct relationship. 
 The 10-year Canadian cohort study presented in a review by Bruyere and Reginster 
(2015) was also looked at in depth for this literature review.  Interestingly, the use of serotonin 
and noradrenaline reuptake inhibitors (SNRIs) was also studied.  These were found to elevate 
risk of fracture as well as SSRIs (Moura, Bernatsky, Abrahamowicz, et al, 2014).  In relation to 
osteoporotic changes, this remains a clinically relevant area of study along with SSRIs prescribed 
for depression.  SNRIs are commonly used for depression and vasomotor symptom control in 
menopausal women, who are already entering a higher fracture risk population. 
Results and Recommendations the Literature. 
 With the current presented evidence, The Study of Osteoporotic Fractures have deemed 
SSRI use an independent risk factor from depressive symptoms for fractures.  Their studies 
concluded this from unexpected findings, and have since stated that treating depression with 
SSRIs intensifies the original risk of fracture from depressive symptoms.  Individuals already at 
an increased risk of compromised bone density, due to clinical depression, are being put at an 
even greater risk through SSRI treatment.  Final recommendations from the evaluated literature 
concluded that timely and accurate musculoskeletal evaluations need to be done for patients of 
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current or potential SSRI use.  Further, serial evaluations with DEXA scans, early initiation of 
anti-osteoporotic medications, and lifestyle management should be implemented in individuals 
who are at an increased risk at baseline (Fernandes et al., 2016). 
 Bruyere and Reginster (2015) address the issue that SSRI use is not included in the 
FRAX assessment scoring.  They recommend that osteoporosis management be initiated for the 
SSRI population.  If not to be included in the FRAX scoring, this may be done on an individual 
level.  With the presented evidence, it is apparent that there needs to be a discussion between 
providers and patients to educated SSRI uses that they may need to be monitored for bone health 
complications. 
 Further, Hant and Bolster (2016) conclude in their research that SSRIs on a list of 
medications that may harm bone.  They recommend that health care providers closely monitor 
the bone density of individuals on any glucocorticoids, proton pump inhibitors, aromatase 
inhibitors, certain antiepileptic medications, and selective serotonin reuptake inhibitors.  By 
closely monitoring these patients, osteoporotic prevention treatment can be initiated as needed. 
 Warden and Fuchs (2016), skeptically look at recent meta-analyses on SSRIs and 
fractures.  Their findings were that these studies report a 70% increase in fracture risk when 
taking an SSRI.  Conversely, the authors here feel recent meta-analyses were “observational and 
limited in their ability to establish causality” (p.211).  After using the Bradford Hill criteria to 
rule out a weak association between SSRI and fractures, they did conclude a strong and 
consistent relationship between SSRIs and fractures.  Warden and Fuchs (2016) demonstrated 
that although a strong relationship is present, many studies have limitations and confounding 
variables that remain a concern.  Even with limitations preventing them from completely 
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accepting the results, they do recommend bone density testing and interventions for SSRI users 
presenting with additional risk factors. 
Premenopausal versus postmenopausal women 
 Premenopausal fracture occurrence is much lower, and not related to BMD as fractures 
are in postmenopausal women.  Because of this, postmenopausal diagnostic criteria and 
treatment guidelines cannot apply to this population.  Screening in this population is up to the 
provider, and performed on an independent basis.  Current best practice guidelines notify 
providers that it may be appropriate to screen for premenopausal osteoporosis if any of the 
following occur; a low trauma fracture from standing height or less, causes of estrogen 
deficiency, drugs including glucocorticoids, anticonvulsants, antidepressants, and high doses of 
steroids, and similar risk factors to the postmenopausal population (Becker, 2017, as stated in Up 
to Date).  Providers must be proactive in their risk assessment.  The responsibility of identifying 
risk factors in premenopausal women, screening for osteoporosis, and early interventions truly 
falls on individual providers.  
Conclusion and Clinical Practice Proposal 
 The presented evidence proposes a strong association between SSRI use and 
osteoporosis, independent of other variables.  Although more randomized controlled trials may 
be needed to strengthen the evidence, and decrease the limitations of the studies, the presence of 
a negative association is clear through this literature review. 
 Aside from SSRI implications on bone health, osteoporosis screening numbers need to be 
improved in primary care.  Screening guidelines may need to be altered to become more specific, 
urging providers of its importance.  Including the use of SSRIs in the FRAX calculator or 
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flagging providers to assess bone health before prescribing an SSRI would be beneficial to 
patient outcomes. 
Learning Points 
• Providers should understand the potential implications of SSRIs on bone health 
• Assessing bone health risk factors at all ages is a crucial component to preventative care 
• High risk osteoporotic fracture patients should have an in-depth bone health assessment 
completed before starting an SSRI, this may include a DEXA scan and screening before 
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